Increased deal activity by the European Investment Bank as the Horizon 2020 program phases out

The program has become an important pillar in the European venture financing landscape to promote R&D projects of fast-growing companies from sectors such as ICT, deep tech, and life sciences.

Starting in 2015, the EIB has supported over 71 life sciences deals with their debt financing programs, providing a total funding volume of EUR 1.6bn over its lifetime.

As the program came to an end in 2021, the EIB has financed a record of 19 life sciences companies in its last year with a total funding volume of EUR 327m.

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here: